|
wild type
|
BAO_0000089 |
|
|
methylated
|
BAO_0000088 |
|
|
posttranscriptionally modified
|
BAO_0002158 |
|
|
spastic hemiplegia
|
DOID_10967 |
|
|
spastic cerebral palsy
|
DOID_0050669 |
|
|
activation
|
BAO_0000087 |
|
|
reversible binding
|
BAO_0000086 |
|
|
ligand binding mode of action
|
BAO_0000476 |
|
|
spastic diplegia
|
DOID_10965 |
|
|
irreversible binding
|
BAO_0000085 |
|
|
mode of action
|
BAO_0000074 |
|
|
EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor
|
CHEBI_50423 |
|
|
EC 1.6.3.* (oxidoreductase acting on NADH or NADPH with oxygen as acceptor) inhibitor
|
CHEBI_76867 |
|
|
platelet aggregation inhibitor
|
CHEBI_50427 |
|
|
hematologic agent
|
CHEBI_50248 |
|
|
oophoritis
|
DOID_10974 |
|
|
ovarian disease
|
DOID_1100 |
|
|
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
|
CHEBI_63721 |
|
|
EC 2.1.2.* (hydroxymethyl-, formyl- and related transferases) inhibitor
|
CHEBI_76874 |
|
|
EC 2.1.1.45 (thymidylate synthase) inhibitor
|
CHEBI_63720 |
|
